Participated · Seed · Jan 2026

Nanochon is building Chondrograft™, a patented implant designed to restore articular cartilage in the knee while allowing immediate weight-bearing and motion. The technology targets young, active patients who have failed conservative therapies and currently face costly, invasive, and often short-lived treatment options. The company is about to launch a 10-patient, phase-I first-in-human clinical study in Canada to assess Chondrograft’s safety and efficacy, and is already planning a larger North American pivotal trial aimed at eventual FDA clearance. Beyond the implant, Nanochon has partnered with ProVoyance to create an MRI-based pre-operative surgical-planning software platform. The newly raised capital will also accelerate manufacturing capabilities and deepen R&D. Including the latest round, Nanochon has secured a total of $11.3 million in funding to date, underscoring strong investor confidence in its approach.

Participated · Series B · Dec 2025

Aeovian Pharmaceuticals is focused on restoring cellular metabolic quality control through highly selective inhibition of mTORC1 or CD38. Its lead candidate, AV078, is a first-in-class, CNS-penetrant selective mTORC1 inhibitor engineered to bypass the toxicities seen with non-selective mTOR blockers such as everolimus. Following encouraging Phase 1 data, AV078 is being advanced into a Phase 2 proof-of-concept trial for patients with TSC-related refractory epilepsy, a condition that affects roughly one million people worldwide and remains resistant to therapy in about two-thirds of cases. The company’s wholly owned pipeline aims to expand selective mTORC1 inhibition to additional rare and age-related indications. Proceeds from its recent financing will support the Phase 2 study and further pipeline development. Aeovian operates out of Berkeley, California and remains privately held; no revenue or user metrics were disclosed in the article.

Participated · Equity · Dec 2025

Empathy Health Technologies is the company behind Sober Sidekick, a free mobile application that connects individuals battling substance-use disorders with a 24/7 peer community, daily motivation, professional help and on-demand AA meetings. The app encourages users to both give and receive supportive messages and leverages an “empathy algorithm” that analyzes behavioral and language patterns to predict relapse risk, automatically triggering outreach when danger signs surface. Sober Sidekick has been downloaded nearly 1.1 million times, serves more than 145,000 monthly active users and has facilitated over 2 million peer interactions; an independent analysis found that five interactions on the platform correlate with a 68 % lower likelihood of relapse. While anyone can download the app for free, the company also signs value-based contracts with commercial and public payers. Revenue details were not disclosed, but Empathy Health intends to build a continuous-care infrastructure that shifts reimbursement from crisis response to relapse prevention. With its newest capital, the firm plans to deepen payer partnerships, enhance its predictive technology, and expand member-support operations, including data-science capacity and care-navigation infrastructure. Founded by CEO Chris Thompson, who drew on his own recovery experience, the company ultimately aims to redefine success in substance-use care by measuring sustained relapse prevention rather than episodic treatment.

Participated · Equity · Nov 2025

Founded in 2020, Iambic Therapeutics integrates pioneering AI models, such as its Enchant multimodal transformer and NeuralPLexer structure predictor, with automated chemistry to run weekly design-make-test cycles. The platform is used to generate differentiated development candidates and has already delivered new drugs into human trials with what the company claims is unprecedented speed. Its lead asset, IAM1363, has shown anti-tumor activity and a favorable safety profile in HER2-wild-type and HER2-mutated cancers, and is now part of a clinical collaboration with Jazz Pharmaceuticals. Additional internal programs targeting KIF18A and CDK2/4 are expected to enter the clinic soon. Iambic is also engaged in a technology-enablement collaboration with Revolution Medicines that pairs proprietary data with NeuralPLexer capabilities. The company advances both wholly owned and partnered pipelines aimed at addressing urgent unmet needs. Backed by a recent oversubscribed financing of more than $100 million, Iambic is positioned to expand its pipeline, partnerships, and platform innovations.

Participated · Series A · Feb 2025

SingleFile provides automated compliance solutions designed to help businesses navigate complex regulatory environments. Led by CEO Aaron Finn, the company emphasizes innovation and customer success in legal and compliance technology. It intends to use the $9M Series A to expand operations and IT development efforts. The company added Mindy Lauck as Chief Product Officer and Teresa Kotwis as Chief Financial Officer. Since its 2019 founding, SingleFile has raised over $24M in total funding, including $15M in the past 12 months. The article does not disclose revenue or user metrics. SingleFile provides cloud-based compliance software to automate filings to local, state, and federal agencies, aiming to replace email, PDFs, and spreadsheets in the compliance process. Its product set covers Corporate Transparency Act (CTA) compliance, company formation documents, business license renewals, employee-related filings, and state franchise, excise and use taxes. The startup sells to law firms (including Wilson Sonsini, Fenwick and Gunderson Dettmer) and customers in venture capital, private equity and real estate. SingleFile positions itself as the “Stripe of compliance,” seeking to pull company data from systems of record and pass it to government agencies with minimal human interaction. The company is focused on the U.S. market, was incubated out of Pioneer Square Labs, and employs more than 25 people. CEO Aaron Finn (joined 2021) and founder/CL O Sean Flynn are leading growth as regulatory changes such as the CTA create demand tailwinds. SingleFile provides technology that files formation documents and annual reports with secretary of state offices, effectively acting as a registered‑agent and compliance filing platform. Its service is used by law firms (including Wilson Sonsini, Fenwick and Gunderson Dettmer) and by customers across venture capital, private equity and real estate. Customers named in the article include Techstars, AngelList, High Alpha Innovation and Pacific Current Partners. The company spun out of Pioneer Square Labs and is a Seattle‑based business; Wilson Sonsini is both a partner on its Neuron startup platform and an investor. SingleFile has 10 full‑time employees, and CEO Aaron Finn said revenue has grown 3X in the past 18 months. Founder Sean Flynn remains with the company as chief growth officer; Finn joined as CEO in 2021. SingleFile is a Seattle-based startup offering an online filing and registered agent platform that simplifies filing and compliance workflows for companies and law firms. The company launched its beta product in 2019 and has processed thousands of orders from hundreds of customers. It works with six national law firms and is a technology partner for Wilson Sonsini’s Neuron startup platform. Law firms use SingleFile to file formation documents, act as registered agent, and track and file annual reports to avoid falling out of good standing. The company has 10 employees and expects to add three or four more in the near term. Management was bolstered with Aaron Finn named CEO while founder Sean Flynn shifted to chief growth officer to focus on customer acquisition and operations; the new capital is intended to scale the business and accelerate growth.